By pooling data from 20 RCTs, researchers analyzed the adverse event rate with empagliflozin versus placebo in 2367 T2DM patients with moderate to severe CKD.

Three experts talk about findings from clinical trials with the non-steroidal MRA finerenone in patients with CKD and T2DM and how to implement these findings in daily clinical practice.

AHA 2021 It is not clear yet what the effect of aspirin is on the risk of dementia in patients with T2DM. Prof. Armitage presents a study in which this was investigated using data of the ASCEND trial.

AHA 2021 Using data of the ASCEND trial, this study showed that there was no significant effect of aspirin on dementia outcomes compared to placebo in patients with T2DM.

ESC 2021 The FIGARO-DKD trial showed that the nonsteroidal MRA finerenone significantly reduced the risk of CV outcomes in patients with mild-to-moderate kidney disease and diabetes.

ESC 2021 FIDELITY was a prespecified pooled analysis of FIDELIO-DKD and FIGARO-DKD, which showed that finerenone reduced the risk of CV and renal outcomes in patients with T2DM and mild-to-severe CKD.

This study showed that estimated age-standardized prevalence of diabetes among US adults increased significantly from 9.8% in 1999-2000 to 14.3% in 2017-2018. In 2015-2018, only 21.2% of adults with diagnosed diabetes achieved individualized HbA1C targets, BP <130/80 mmHg, and LDL-c <100 mg/dL.

Microvascular disease (MVD) was associated with the development of HF in adults with T2DM, independently of traditional risk factors including CAD.

ESC HF 2021 Use of empagliflozin was associated with reduced risk of CV and renal events, and all-cause mortality compared to use of DPP-4i in T2DM patients in a real world setting.

ACC 2021 Risk of new-onset AF was reduced by 29% in patients randomized to finerenone compared to placebo in a population of patients with T2DM and CKD.

ACC 2021 A pooled patient-level analysis showed that sotagliflozin significantly reduced total CV deaths, HF hospitalizations, and urgent visits for HF across the full range of baseline EF, including in patients with HFpEF.

In the FIGARO-DKD phase 3 trial, the nonsteroidal MRA finerenone reduced the primary endpoint, a composite of CV death and non-fatal CV events, compared to placebo in patients with CKD and T2DM.